Developing a paradigm of drug innovation: an evaluation algorithm

Drug Discovery Today

Volumn 11, Issue 21-22, 2006, Pages 999-1006

  Caprino, Luciano ^a   Russo, Pierluigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; GLITAZONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; RANITIDINE; TERAZOSIN;

ALGORITHM; BIOTECHNOLOGY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HEALTH ECONOMICS; HUMAN; LICENSING; POSTMARKETING SURVEILLANCE; PROSTATE HYPERTROPHY; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; URINARY DYSFUNCTION;

ALGORITHMS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; DECISION TREES; DIFFUSION OF INNOVATION; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 33750023231     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.09.009     Document Type: Review

References (16)

1. Drews J. Basic science and pharmaceutical innovation. Nat. Biotechnol. 17 (1999) 406
2. Di Masi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
3. Frank R.G. New estimates of drug development costs. J. Health Econ. 22 (2003) 325-330
4. Riggs T.L. Research and development costs for drugs. Lancet 363 (2004) 184
5. Rawlins M.D. Cutting the cost of drug development?. Nat. Rev. Drug Discov. 3 (2004) 360-364
6. Dickson M., and Gagnon J.P. Key factors in the rising costs of new drug discovery and development. Nat. Rev. Drug Discov. 3 (2004) 417-429
7. Drews J., and Ryser S. Pharmaceutical innovation between scientific opportunities and economic constraints. Drug Discov. Today 2 (1997) 365-372
8. Preziosi P. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario?. Nat. Rev. Drug Discov. 3 (2004) 521-526
9. Schwartz D., and Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20 (1967) 637-648
10. MacRae K.D. Pragmatic versus explanatory trials. Int. J. Technol. Assess. Health Care 5 (1989) 333-339
11. Schmid E.F., and Smith D.A. Should scientific innovation be managed?. Drug Discov. Today 7 (2002) 941-945
12. Motola D., et al. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br. J. Clin. Pharmacol. 59 (2005) 475-478
13. Tang Z., et al. Quantitative risk modelling for new pharmaceutical compounds. Drug Discov. Today 10 (2005) 1520-1526
14. Chadwick A., and Hajek M. Learning to improve the decision-making process in research. Drug Discov. Today 9 (2004) 251-257
15. Messori A., et al. Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients. Expert Opin. Pharmacother. 5 (2004) 2381-2389
16. Douwes E.A. Assessment of the level of innovativeness of pharmaceutical products. Drug News Perspect. 9 (1996) 532-536